Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TTK | P33981 | 3/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 3/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | ITK | Q08881 | 3/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | FLT1 | P17948 | 2/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.41 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177127 | 0.78 | ESR1 (0.43) | CYP3A4TP53CYP1A2CYP2D6LMNA | |
| SCHEMBL3079936 | 0.78 | BCHE (0.40) | KDM4EALDH1A1GAAALPLHPGD | |
| SCHEMBL16210184 | 0.77 | KDM4E (0.45) | KDM4EIDO1ALDH1A1TTKMAPK10 | |
| SCHEMBL693684 | 0.77 | BCHE (0.47) | KDM4EIDO1ALDH1A1MAPK1NPC1 | |
| SCHEMBL30681831 | 0.75 | KDM4E (0.58) | KDM4EIDO1ALDH1A1TTKMAPK10 | |
| SCHEMBL2353932 | 0.75 | METAP2 (0.47) | KDM4EIDO1ALDH1A1TTKMAPK10 | |
| SCHEMBL2188838 | 0.75 | KDM4E (0.58) | KDM4EIDO1ALDH1A1TTKMAPK10 | |
| SCHEMBL30316649 | 0.75 | KDM4E (0.58) | KDM4EIDO1ALDH1A1TTKMAPK10 | |
| SCHEMBL7543114 | 0.75 | KDM4E (0.43) | KDM4EIDO1ALDH1A1TTKMAPK10 | |
| SCHEMBL1672674 | 0.73 | IDO1 (0.78) | KDM4EIDO1ALDH1A1TTKMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714244-B2 | Substituted pyrido[4,3-d]pyrimidines as Wee-1 inhibitors | ALMAC DISCOVERY LIMITED (GB) | 2017-07-25 | — | — | US | disclosed |
| US-9434698-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9345702-B2 | Methods of treatment using selective Bcl-2 inhibitors | ABBVIE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160060258-A1 | 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-20150191437-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150150870-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
| US-8980643-B2 | Dicationic liquid salts and methods of use thereof | SIGMA-ALDRICH CO., LLC (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2778166-A1 | THIOXANTHENE DERIVATIVES FOR THE TREATMENT OF INFECTIOUS DISEASES | BKG Pharma ApS (DK) | 2014-09-17 | — | — | EP | disclosed |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2004089942-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-1432420-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | Acadia Pharmaceuticals Inc. (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1373494-A2 | SUCCINIMIDE AND MALEIMIDE DERIVATIVES AND THEIR USE AS TOPOISOMERASE II CATALYTIC INHIBITORS | Topo Target A/S (DK) | 2004-01-02 | — | — | EP | disclosed |
| EP-1341743-A2 | ORGANIC REACTIONS WITH CO GENERATING MATERIALS | Personal Chemistry i Uppsala AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003028650-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| US-20030032625-A1 | Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors | TOPO TARGET APS (DK) | 2003-02-13 | — | — | US | disclosed |
| WO-2002078679-A2 | SUCCINIMIDE AND MALEIMIDE DERIVATIVES AND THEIR USE AS TOPOISOMERASE II CATALYTIC INHIBITORS | TOPO TARGET APS (DK) | 2002-10-10 | — | — | WO | disclosed |
| US-20020103176-A1 | Male contraceptive formulation comprising norethisterone | SCHERING AKTIENGESELLSCHAFT | 2002-08-01 | — | — | US | disclosed |
| WO-2002048072-A2 | ORGANIC REACTIONS WITH CO GENERATING MATERIALS | PERSONAL CHEMISTRY I UPPSALA AB (SE) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060258-A1 | 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS | WEE1, WEE2, NME1 | KDM4E 420/4885IDO1 1091/4885ALDH1A1 1226/4885 |
| US-20030032625-A1 | Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors | TOP2A, TOP2B, TOP1 | KDM4E 1093/4885IDO1 3106/4885ALDH1A1 2038/4885 |
| US-20020103176-A1 | Male contraceptive formulation comprising norethisterone | NR5A1, NASP, SHBG | KDM4E 1312/4885IDO1 3006/4885ALDH1A1 2153/4885 |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM5, CHRM1 | KDM4E 1250/4885IDO1 1557/4885ALDH1A1 3046/4885 |
| US-20150150870-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | KDM4E 2326/4885IDO1 2741/4885ALDH1A1 4772/4885 |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ACVR1, ACVR1B | KDM4E 778/4885IDO1 1775/4885ALDH1A1 161/4885 |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | KDM4E 1090/4885IDO1 3419/4885ALDH1A1 2353/4885 |
| US-20150191437-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | KDM4E 3729/4885IDO1 1571/4885ALDH1A1 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.